How to Buy Insight Molecular Diagnostics Stock
Insight Molecular Diagnostics Inc
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
Insight Molecular Diagnostics stock last closed at $5.82, up 7.58% from the previous day, and has increased 169.44% in one year. It has overperformed other stocks in the Diagnostics & Research industry by 1.53 percentage points. Insight Molecular Diagnostics stock is currently +202.81% from its 52-week low of $1.92, and -31.61% from its 52-week high of $8.51.
At the moment, there are 28.66M IMDX shares outstanding. The market value of IMDX is $166.83M. In the past 24 hours, 15,700 IMDX shares were traded.
How to Buy Insight Molecular Diagnostics Stock
Wondering how to invest in Insight Molecular Diagnostics stock? Here's how.
- Choose where to buy Insight Molecular Diagnostics stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Insight Molecular Diagnostics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Select your method of payment and add your info.
- Analyze Insight Molecular Diagnostics stock: The Insight Molecular Diagnostics ticker symbol is IMDX. Is Insight Molecular Diagnostics stock a good investment? Should you buy shares of IMDX? How do IMDX's underlying business fundamentals look? Do top analysts think Insight Molecular Diagnostics is a good buy? Why has IMDX's stock price moved recently? (Hint: Our stock market research tools can help you understand if IMDX is a good stock to buy).
- Execute your IMDX buy order: Decide if you will purchase IMDX shares at the current market price or use a limit order to buy IMDX shares at a given price.
- Get updates on your investment in IMDX: Create a watchlist to keep track of your position in Insight Molecular Diagnostics stock.
Step 1: Choose where to buy Insight Molecular Diagnostics stock
You need an online brokerage account to access the NASDAQ market and buy IMDX shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal information so you are able to buy IMDX today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start your new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've opened your account on the best stock app, your next step is to transfer the money for your investment:
Watch the video below if you need help transferring money into your new investment account.
Step 4: Analyze Insight Molecular Diagnostics stock
Once you have figured out the best place to buy Insight Molecular Diagnostics stock, it's absolutely critical to research their stock before you invest, so you actually wrap your head around the risk as well as the upside.
Insight Molecular Diagnostics stock quick numbers
Insight Molecular Diagnostics Due Diligence Score
WallStreetZen was designed to help average investors perform more accurate fundamental analysis in less time.
You can see all of the due diligence checks on IMDX's stock page.
Is IMDX stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge IMDX's intrinsic value.
You can do additional valuation research on IMDX's stock here.
How do IMDX Financials look?
Passed Financial Due Diligence Checks:
- IMDX has $19.42M in cash and short term investments. This is sufficient to cover its annual cash burn of $23.91M.
- There are more short-term assets than short-term liabilities on the IMDX balance sheet.
Failed Financial Due Diligence Checks:
- IMDX has cash burn of 23909000. It does not have enough cash and short-term investments to cover this.
- Total IMDX debt is still negative.
- IMDX profit margin has gone up by 47.7 percentage points in the past year, but the company is still unprofitable.
- IMDX debt to equity ratio of -5.78 is negative.
- There are more long-term liabilities than short-term assets on the IMDX balance sheet.
Is it a good time to buy Insight Molecular Diagnostics stock, according to Wall Street analysts?
Out of 1 Wall Street analysts who monitor IMDX, the consensus analyst rating on IMDX is a Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are saying on the Insight Molecular Diagnostics stock forecast page.
IMDX Trading Indicators
IMDX Earnings
Last year, IMDX revenue was $4.40M. During the last 5 year, IMDX's revenue has grown by 43.88% per year. This was faster than the Diagnostics & Research industry average of 9.39%.
Learn more about IMDX's earnings and revenue performance here.
What are IMDX insiders up to?
In the past year, executives and large shareholders at IMDX have bought more shares than they have sold.
Andrea S. James, Chief Financial Officer of IMDX, was the latest IMDX insider to sell. They sold $73,171.75 worth of IMDX shares on Oct 31, 2025.
Learn more about who owns IMDX stock here.
Can I get consistent income from IMDX stock?
No, Insight Molecular Diagnostics doesn't provide an income stream by paying out dividends.
What others are saying about IMDX
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your IMDX buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular price limit, use a limit order.
Click the Open Trade button and eToro will execute the order.
If you need more assistance buying stocks on eToro, click the how to video below:
Step 6: Get updates on your investment in IMDX
Now that you own some IMDX shares, you'll want to keep up with your new investment.
Make a watchlist to keep track of your IMDX stock.
IMDX Feed
How to Buy Stock in Insight Molecular Diagnostics
To summarize, here are the 6 steps for buying Insight Molecular Diagnostics stock:
- Choose where to buy Insight Molecular Diagnostics stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Insight Molecular Diagnostics stock
- Execute your IMDX buy order
- Get updates on your investment in IMDX
If you require a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Insight Molecular Diagnostics, hit the button below to create your watchlist.
More Content You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.